NxStage Medical, Inc. Sustainability Profile
NxStage Medical, Inc., a leading innovator in the renal care industry, is headquartered in the United States. Founded in 1998, the company has made significant strides in transforming dialysis treatment through its advanced technologies. NxStage is renowned for its portable dialysis systems, particularly the System One, which offers patients greater flexibility and independence in managing their kidney disease. With a strong presence across North America and Europe, NxStage Medical focuses on home dialysis solutions, aiming to enhance patient quality of life. The company has achieved notable recognition for its commitment to patient-centric care and has established itself as a key player in the renal care market. Through continuous innovation and a dedication to improving treatment outcomes, NxStage Medical remains at the forefront of the industry.
DitchCarbon Score
How does NxStage Medical, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
NxStage Medical, Inc.'s score of 56 is higher than 75% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
NxStage Medical, Inc., headquartered in the US, currently does not have specific carbon emissions data available for recent years. The company is a current subsidiary of Fresenius Medical Care AG, which influences its climate commitments and emissions reporting. As part of this corporate family, NxStage Medical inherits sustainability initiatives and targets from Fresenius Medical Care AG, including those related to the Science Based Targets initiative (SBTi) and the Carbon Disclosure Project (CDP). While specific reduction targets for NxStage Medical are not detailed, the overarching commitments from Fresenius Medical Care AG suggest a focus on reducing carbon emissions across their operations. This includes efforts to enhance sustainability practices and improve energy efficiency, although no absolute emissions figures or specific reduction achievements have been disclosed for NxStage Medical itself. As the company continues to align with its parent organisation's climate strategies, it is expected to contribute to broader industry efforts aimed at mitigating climate change impacts.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|
| Scope 1 | - | - | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000.0 |
| Scope 2 | 557,200,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 3 | - | - | - | - | - | 0,000,000,000 | 0,000.0 |
How Carbon Intensive is NxStage Medical, Inc.'s Industry?
How Carbon Intensive is NxStage Medical, Inc.'s Location?
NxStage Medical, Inc.'s Scope 3 Categories Breakdown
NxStage Medical, Inc.'s Scope 3 emissions, which decreased by 100% last year and decreased by approximately 100% since 2023, demonstrating supply chain emissions tracking. Their carbon footprint includes supplier sustainability and value chain emissions data across Scope 3 categories, with "Purchased Goods and Services" being the largest emissions source at 17640922% of Scope 3 emissions.
Top Scope 3 Categories
NxStage Medical, Inc.'s Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
NxStage Medical, Inc. has established climate goals through participation in recognized frameworks and target-setting initiatives. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
B. Braun Medical Inc.
Asahi Kasei Kuraray Medical Co.,Ltd.
Asahi Kasei Medical Co., Ltd.
Gambro, Inc.
Let us know if this data was useful to you
Usage Policy
You're welcome to quote or reference data from this page, but please include a visible link back to this URL.
Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.